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Abstract: Myogenesis is the biological process by which skeletal muscle tissue forms. Regulation of
myogenesis involves a variety of conventional, epigenetic, and epigenomic mechanisms that control
chromatin remodeling, DNA methylation, histone modification, and activation of transcription
factors. Chromatin remodeling enzymes utilize ATP hydrolysis to alter nucleosome structure and/or
positioning. The mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) family of chromatin
remodeling enzymes is essential for myogenesis. Here we review diverse and novel mechanisms of
regulation of mSWI/SNF enzymes by kinases and phosphatases. The integration of classic signaling
pathways with chromatin remodeling enzyme function impacts myoblast viability and proliferation
as well as differentiation. Regulated processes include the assembly of the mSWI/SNF enzyme
complex, choice of subunits to be incorporated into the complex, and sub-nuclear localization of
enzyme subunits. Together these processes influence the chromatin remodeling and gene expression
events that control myoblast function and the induction of tissue-specific genes during differentiation.
Keywords: myogenesis; chromatin remodeling enzymes; cell signaling; SWI/SNF
1. Introduction
1.1. The Family of SWItch/Sucrose Non-Fermentable (SWI/SNF) Chromatin Remodeling Enzymes
Chromatin remodeling enzymes use the energy of ATP hydrolysis to alter histone:DNA contacts in
nucleosomal DNA to modify the position or to disrupt the structure of nucleosomes. The consequences
of these changes include permitting or restricting access of DNA binding regulatory factors to the
chromatin, which can lead to changes in the ability of these factors to regulate DNA-templated processes
such as transcription, replication, repair, and recombination. Most chromatin remodeling enzymes are
multi-subunit complexes consisting of an ATPase and auxiliary proteins that help specify function.
Several families of chromatin-remodeling complexes have been described to date. These include
the SWI/SNF, ISWI, INO80, and CHD complexes [1–7]. Components of the SWI/SNF (SWItch/Sucrose
Non-Fermentable) complex were initially discovered in Saccharomyces cerevisiae as essential for
transcription of genes involved in the mating-type switching and sucrose fermentation pathways [8–10].
Some of these SWI and SNF gene products were shown to form a multi-subunit complex that worked to
oppose the repressive effects of chromatin [11,12]. Subsequent in vitro work demonstrated that purified
SWI/SNF complexes from yeast and human cells altered nucleosome structure in an ATP-dependent
manner and, as a consequence, facilitated nucleosome binding by transcription factors (TFs) [11–15].
Conclusive evidence of catalysis by SWI/SNF complexes followed [16].
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In Drosophila melanogaster, a complex called BAP, which is homologous to the yeast SWI/SNF
complex, is required for expression of homeotic and segmentation genes and regulates the wingless
signaling pathway [17–21]. These functions are essential for development since deletion of BAP
subunits during embryogenesis is lethal [22,23]. Not surprisingly, depletion of many of the mammalian
SWI/SNF (mSWI/SNF) subunits in mice also results in embryonic or peri-natal lethality [23,24].
In mammalian cells, the first evidence for SWI/SNF enzyme function showed a role as a cofactor
for transcriptional activation by nuclear hormone receptors [25–27]. Subsequent studies demonstrated
that its co-activator function was mediated by direct chromatin remodeling activity on integrated
viral genes or endogenous cellular genes [28,29]. Additional studies implicated the mSWI/SNF
chromatin remodeling enzyme activity in promoting transcriptional repression, as well as other DNA
transactions [30–36].
The mSWI/SNF complex is present in multiple divergent forms [13,15,37–40]. Two homologous,
mutually exclusive ATPases, called BRM (Brahma) and BRG1 (Brahma related gene 1) can act as
the catalytic subunit for mSWI/SNF enzyme complexes [25–27]. At least 11 additional subunits,
or BRG1/BRM-associated factors (BAFs), are structural and functional components of the mSWI/SNF
enzyme complexes. Many of these subunits are orthologous to subunits of yeast SWI/SNF and Drosophila
BAP complexes [25,26,41–43]. The existence of splice variants, multiple isoforms of some of the
subunits, and tissue-specific gene expression results in the possibility of hundreds of different potential
combinations of proteins in any given enzyme complex, and it is widely believed that the combination
of subunits that are present determines the functional specificity of the enzyme [44,45]. Recent
efforts have significantly advanced understanding of enzyme complex assembly by demonstrating
step-wise assembly of three main sub-families of mSWI/SNF complexes [40]. The links between enzyme
composition and function, however, remain poorly understood.
Subunit composition is not the only mechanism by which chromatin remodeling enzyme
function can be regulated. Post-transcriptional modifications such as acetylation, methylation,
sumoylation, phosphorylation, among others, modulate the activity of the mSWI/SNF complex [46–54].
Signaling pathways involve a fine-tuned, differential regulation of kinases and phosphatases that
are essential for lineage determination and tissue development and maturation [55–57]. Protein
kinases and phosphatases direct cell fate through the reversible processes of phosphorylation and
dephosphorylation, respectively. Hundreds of these enzymes and specific targets are known in higher
eukaryotes, and have been reviewed elsewhere [58–61]. However, our understanding of regulated
phosphorylation to control chromatin remodeling processes in the context of lineage determination
and differentiation is limited. Emerging evidence has shown that signal transduction pathways are
involved in the phosphorylation of subunits of the mSWI/SNF complex, modulating its catalytic
activity and its cofactor function during tissue differentiation. Here we summarize work examining
modulation of phosphorylation of mSWI/SNF subunits that functionally impacts myoblast proliferation
and differentiation.
1.2. Myogenesis
The development of skeletal muscle is a complex, multi-step process in which mesoderm-derived
structures form somites that then serve as the source for all skeletal muscles in the body. Somites
are transient paired structures that align on either side of the neural tube around day 8 of mouse
embryogenesis. Somitic cells will commit to specific lineages, including skeletal muscle, due to the
influence of signaling molecules produced around the periphery [62–68]. Initial events give rise to the
embryonic or primary muscle fibers of the organism, which lead to the subsequent development of
fetal (secondary) fibers that will be the foundation of future adult muscles [65,66,69–73]. Embryonic
development of skeletal muscle is established in a multi-step cellular process that involves the activation
of gene expression programs to generate the different precursor cell types [62,66,74–76]. In mice,
skeletal muscle generation begins from embryonic day 8.5 to 9 (E8.5–E9) to E18.5; muscle maturation
continues for 2–3 weeks after birth.
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Post-natal skeletal muscle stem cells, called satellite cells, exist in a quiescent state under the
basal lamina of skeletal muscle fibers and are activated upon muscle injury or hypertrophy signaling.
Homeostasis of mature skeletal muscle tissue also requires the activation and mitotic expansion of
satellite cells as a mechanism to maintain terminally differentiated myofibers [69,71,77–84]. Maintenance
of a functional satellite cell pool relies on a specific transcriptional program. Pax7 is the TF required for
maintenance and proliferation of satellite cells [80,82,85,86]. Deletion of Pax7 in murine models led
to death within 2–3 weeks after birth [87]. Mice depleted of Pax7 have a reduced satellite cell pool,
and fail to regenerate muscle [88–90].
A wide variety of signaling molecules drive the development of skeletal muscle from embryonic
stages throughout post-natal growth [91,92]. Cell signaling events are translated into the activation of
myogenic TFs and chromatin remodelers in an organized manner during the maturation of the lineage.
The mechanisms by which the cells integrate these signals to define and establish the myogenic lineage
are the subject of intense investigation. Here, we will discuss emerging roles for different kinases and
phosphatases in the regulation of transcription and chromatin remodeling mechanisms associated with
growth and differentiation of the skeletal muscle lineage.
2. Cell Signaling Pathways Modulate Chromatin Remodeling Enzyme Function during Skeletal
Muscle Myogenesis
Multiple groups determined many years ago that most, if not all, of the mSWI/SNF subunits
were phosphoproteins [93–96]. Despite this knowledge, there has been little progress in determining
the functional role of mSWI/SNF subunit phosphorylation, nor has there been significant attention
given to the identification of the kinases and phosphatases that generate and regulate phosphorylation.
Indeed, the vast majority of our current understanding of mSWI/SNF phosphorylation is limited to
modification of the two ATPase subunits, BRG1 and BRM, and of BAF60c, one of three isoforms of the
BAF60 protein.
The BRG1 ATPase is essential for viability, proliferation, and differentiation of myoblasts [29,97].
Functional distinctions between the BRG1 and BRM ATPases in the regulation of myogenesis have
been identified [98], suggesting non-overlapping roles, but a full understanding of the divergence in
the roles of these ATPases is lacking. The BAF60c protein is the BAF60 isoform most highly expressed
in skeletal muscle [41], and it is required for normal skeletal muscle development [99]. BAF60 proteins
have long been implicated as core mSWI/SNF subunits [40,100], though their molecular role as part of
the complex is poorly defined.
2.1. The Stress Responsive P38 Kinase Is a Regulator of Chromatin Remodeling Enzymes during Myogenesis
Mitogen-activated protein kinases (MAPKs) phosphorylate the OH- groups of serine/threonine
residues to regulate cellular processes such as proliferation, differentiation, survival, and apoptosis.
Some members of this kinase family influence the development of skeletal muscle. For instance,
extracellular signal-regulated kinase ERK1/2 is critical for myoblast proliferation, and ERK2 is necessary
for myocyte fusion [101,102]. ERK activity also promotes the transcriptional activity of MyoD by
an undefined mechanism [103]. Maintenance of quiescent satellite cells also relies on the ERK
pathway [104].
P38 is the only MAPK that has been demonstrated to directly affect the activity of the mSWI/SNF
complex. P38 responds to mitogens as well as a wide range of extracellular stress stimuli [105]. There are
four widely expressed, highly homologous p38 isoforms (α, β, γ, and δ). P38α is ubiquitously expressed,
whereas the other isoforms show differential expression across tissue types (reviewed in [105–108]).
Over 100 direct targets for p38-mediated phosphorylation have been identified [105,109], demonstrating
the broad effects of p38 function. P38 kinases are well-known for regulating pro-inflammatory
signaling networks and the biosynthesis of cytokines, such as the tumor necrosis factor-α (TNF-α) and
interleukin-1β (IL-1β) in immune cells [110–112].
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P38 is a key regulator of skeletal muscle differentiation, with extensive investigation identifying
multiple mechanisms of action in satellite cells, in immortalized myoblasts, and in cells of other
origins that have been reprogrammed to recapitulate skeletal muscle differentiation [113–124]. During
myogenesis, there is a sustained increase in the amount of activated p38α and β [125–127]. Activation
of p38α induces cell cycle withdrawal by upregulating the activity of a different class of MAPK,
the c-Jun N-terminal kinase (JNK) and cyclin D1 expression [119]. p38 phosphorylation of the
Polycomb group repressor Ezh2 facilitates its interaction with the Pax7 locus, thereby promoting
silencing of this essential satellite cell marker gene [128]. In contrast to functions that inhibit
precursor cell properties, p38 also directly promotes myogenic differentiation by phosphorylating
E proteins to increasing their dimerization with lineage-determining MyoD and MyoD-related
TFs [115], a step necessary for the activation of skeletal muscle-specific gene expression. In addition,
p38 phosphorylates MEF2 TFs that cooperate with MyoD family members to activate myogenic gene
expression (Figure 1) [122,126,127,129–131].
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Figure 1. P38 has pleiotropic effects during skeletal muscle differentiation. Phosphorylation
of transcription factors (TFs) (E-proteins, Mef2) and the mSWI/SNF subunit BAF60c by p38
enables expression of myogenic genes and differentiation. P38-dependent phosphorylation of Ezh2
downregulates the expression of Pax7. P38 also induces cell cycle withdrawal by activating c-Jun
N-terminal kinase (JNK) and Cyclin D1.
The link between p38 and chromatin remodeling enzyme function derives from work showing
that p38 kinase is recruited to myogenic promoters at the onset of differentiation and that its activity is
necessary for the recruitment of the mSWI/SNF ATPases BRG1 and BRM to myogenic promoters [114].
These steps are essential for the activation of transcription at muscle-specific genes [29,114,132].
Interestingly, the mSWI/SNF subunit initially identified as the target of p38-mediated phosphorylation
was not one of the ATPases but instead the BAF60c subunit [114]. Subsequent efforts showed
that the BAF60c subunit, but not the ATPase subunits, formed a pre-assembled complex with
MyoD that marks the promoters of myogenic target genes prior to the onset of differentiation
signaling. Importantly, knockdown of BAF60c reduced MyoD binding in undifferentiated cells. During
myogenesis, p38 phosphorylates the BAF60c subunit at threonine 229, permitting the recruitment of
the mSWI/SNF complex ATPases to myogenic promoters and allowing the formation of a functional
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mSWI/SNF enzyme [114,133]. Chromatin remodeling then permits stable access of MyoD to its
cognate binding sites [132] and further recruitment of additional MyoD-associated co-activators
(Figure 1) [133]. This work identified function for an mSWI/SNF subunit independent of the ATPase
subunits and promoted the idea of physical separation of different mSWI/SNF subunits in myoblasts
when biochemical purification of mSWI/SNF enzymes generally have not revealed the existence of
sub-complexes [13–15,94]. Recent characterization of mSWI/SNF assembly showed that the ATPase
subunits are among the last components to be added to the complex [40], which provides further
support for this concept. Intriguingly, BAF60c facilitates the recruitment of BRG1 and TFs such as
GATA4 to target genes in cardiac progenitors [99,134], but whether phosphorylation by p38 is involved
in this process remains to be determined.
The work establishing p38 as a regulator of the mSWI/SNF chromatin remodeling enzymes marked
the first evidence that phosphorylation of subunits could contribute to the assembly of the enzyme
complex. The work also provided further evidence and support for the idea that myogenic genes are
marked for expression in precursor cells, even before the onset of differentiation. Thus, p38 signaling
contributes to the activation of gene expression by modulating the activity of chromatin remodelers in
addition to regulating TFs.
2.2. The Pleiotropic Network of AKT Converges on BAF60c to Promote Myogenesis
AKT, also known as protein kinase B, is a serine/threonine kinase broadly required for cell
proliferation and migration, gene expression, and apoptosis [135]. Three isoforms of AKT (1, 2, and 3)
have been reported. AKT1 is required for myoblast proliferation but not for differentiation. AKT2
expression and activity increase during differentiation, which promotes myogenesis. AKT2 is not
required for myoblast proliferation and is unable to rescue Akt1 deficiency in proliferating cells [136–141].
A recent study has connected the cell adhesion molecule-related downregulated by oncogene (Cdo)
and Protein kinase C-related kinase 2 (PKN2) with activation of the AKT signaling pathway [142].
Depletion of Cdo or PKN2 decreased AKT activation and inhibited myogenesis while overexpression of
these proteins increased AKT signaling and enhanced differentiation. Studies revealed that regulation
of differentiation correlated with the recruitment of BAF60c and MyoD to myogenic promoters [142],
though the specific target molecule was not determined. Thus, it remains to be determined whether
AKT signaling directly or indirectly affects mSWI/SNF assembly and function and which AKT isoform
is responsible. Nevertheless, these data suggest that AKT signaling is influencing the ability of BAF60c
to bind to promoters of myogenic genes, whereas p38 signaling activates chromatin-bound BAF60c
via phosphorylation. AKT signaling may therefore precede p38 signaling in regulation of mSWI/SNF
activity. However, other work using a pharmacological inhibitor showed that BRG1 binding to
myogenic promoters was unaffected [143]. The reason for this apparent discrepancy is unclear. It may
result from different modes of AKT activation, or the consequences of PKN2 manipulation on BAF60c
binding may not be significant enough to preclude BRG1 binding.
2.3. Myoblast Cell Cycle Progression and Viability Are Regulated by Casein Kinase 2 (CK2)-Mediated
Phosphorylation of BRG1
Recent studies have demonstrated that casein kinase 2 (CK2) phosphorylates BRG1 in proliferating
primary myoblasts derived from mouse satellite cells [50,51]. CK2 is a serine/threonine kinase that
exists as a tetramer of two catalytic subunits, CK2α or CK2α’, and two regulatory subunits (CK2β).
This kinase is ubiquitously expressed and has more than 300 known substrates [144–146]. Experiments
performed in diverse cultured cell types showed that CK2 inhibition leads to cell cycle inhibition and
death [147–150]. Thus, CK2 has been associated with proliferation, survival, and apoptosis as well
as transcriptional regulation of these processes. Additional work links CK2 to lineage determination
and differentiation of many tissues [151]. In skeletal muscle, CK2 regulates the activity of Pax3, Pax7,
MyoD, and MyoD-related lineage determining TFs [50,152–159]. Studies using immortalized myoblasts
showed that each of the CK2 subunits have differential roles in the determination of the skeletal muscle
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lineage. For instance, CK2α contributes to the activation of the muscle-specific gene program [160],
while CK2α’ contributes to the membrane translocation of fusogenic proteins, thus regulating myoblast
fusion [160]. CK2β was shown to be essential for MyoD expression in proliferating myoblasts [160].
In proliferating primary myoblasts, BRG1 is phosphorylated by CK2, and CK2 inhibition or
mutation of CK2 target sites in BRG1 resulted in altered myoblast proliferation. Myoblasts expressing
a phosphomimetic mutant BRG1 did not proliferate and died. Thus, appropriate regulation of BRG1
phosphorylation by CK2 is required for myoblast survival and normal proliferation. The mechanistic
explanation for these results is tied to compromised chromatin remodeling and transcriptional activity
of BRG1 at the Pax7 locus in cells with dysregulated CK2 phosphorylation of BRG1 [50] (Figure 2). Pax7
is an essential transcriptional regulator that maintains proliferation of muscle satellite cells [80,81,85,86].
Deletion of Pax7 in mice resulted in a decreased number of satellite cells that were progressively
lost with aging, and the animals had an impaired ability to regenerate muscle tissue in response
to injury [88–90,161]. Recent studies demonstrated that the physical interaction between CK2 and
BRG1 occurs specifically during mitosis [51]. Confocal microscopy and co-immunoprecipitation
analyses showed that CK2 and BRG1 co-localize in cells undergoing mitosis in developing somites of
mouse embryos and in primary myoblasts isolated from satellite cells [51]. Importantly, the mitotic
CK2-dependent phosphorylation of BRG1 was conserved across different cell lineages.
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Figure 2. Casein kinase 2 (CK2) modulates mSWI/SNF activity in proliferating myoblasts.
CK2-dependent phosphorylation of Brahma related gene 1 (BRG1) regulates the sub-nuclear localization
and the subunit composition of the mSWI/SNF complex, viability and cell cycle progression, and the
ability to remodel promoter chromatin and promote gene expression that allows myoblast proliferation.
The diagram shows the presence or absence of phosphorylation of BRG1 for illustrative purposes.
The exact number of phosphorylation sites in the presence of the different mSWI/SNF subunits has not
been determined.
Phosphorylation of BRG1 by CK2 also contributes to the localization of BRG1 in the nucleus [50].
Sub-nuclear fractionation of proliferating primary myoblasts showed that endogenous BRG1, as
well as an ectopically expressed wild type version of BRG1, were associated with both the nuclear
matrix and the chromatin [50], consistent with earlier work demonstrating BRG1 can associate with
the nuclear matrix [31,162]. Interestingly, a phosphomimetic mutant form of BRG1, was unable
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to associate with either of these sub-nuclear fractions, and presented higher intra-nuclear mobility,
as measured by FRAP, than wild type BRG1 proteins [50]. A mutant version of BRG1 that prevents
BRG1 phosphorylation at the CK2 target sites associated only with the nuclear matrix and not
with the chromatin fraction. Enzymatic inhibition of CK2 gave the same results. These findings
suggest that sub-nuclear BRG1 localization is dynamic and is regulated by CK2 phosphorylation.
Whether other mSWI/SNF subunits are similarly regulated in their sub-nuclear distribution remains
an open question. Given the hierarchical assembly of mSWI/SNF subunits into functional enzyme
complexes [40], sequestration of different subunits in distinct sub-nuclear compartments provides a
potential mechanism to achieve regulated assembly (Figure 2).
Another consequence of BRG1 phosphorylation by CK2 is the different subunit composition of
the mSWI/SNF complex [50]. BAF155 and BAF170 are structurally related subunits of mSWI/SNF
enzymes [29]. Analysis of mSWI/SNF complex assembly and genetic knockout studies indicate BAFs
155 and 170 are essential for the formation of all mSWI/SNF complexes and for the stability of all
of the other mSWI/SNF subunits [40,163]. Endogenous BRG1 or an ectopically expressed wild type
version of BRG1 preferentially associates with BAF170, while a non-phosphorylatable BRG1 mutant
as well as the endogenous BRG1 from myoblasts treated with CK2 inhibitor preferentially interacts
with BAF155. A phosphomimetic BRG1 mutant interacted poorly with both BAF170 and BAF155.
Thus, CK2 phosphorylation of BRG1 contributes to the regulation of the subunit composition of
the mSWI/SNF complex (Figure 2, [50]). Variation in subunit composition has been associated with
specialization in the function of the complex [44,45]. For instance, studies using mouse ESCs showed
that the expression of the BAF155 subunit is favored over the expression of BAF170, and BAF155 is
preferentially incorporated into BRG1-based SWI/SNF complexes. Upon ESC differentiation into the
neuronal lineage, expression of BAF155 is downregulated, while BAF170 is induced and incorporated
preferentially into the complex [164]. The consequences of incorporating one or the other subunit are
not well understood, but presumably relate to specific chromatin remodeling functions at specific loci
during developmental or other signaling.
Although there is no direct link to myogenesis, studies of BRG1 and BRM during the cell cycle
showed that both ATPases are hyperphosphorylated upon initiation of mitosis and are excluded from
the condensed mitotic chromosomes. The levels of BRG1 remained unaffected, whereas the BRM protein
may be degraded [93,94]. ERK1, another member of the MAPK family, was implicated as the kinase
that phosphorylates BRG1 and BRM and, consequently, inactivates both the ATPase and the chromatin
remodeling activities of the mSWI/SNF complex during mitosis [94]. Mitotic condensation of the
chromosomes leads to changes in the activities of TFs, cofactors, and RNA polymerase, causing a general
repression of transcription and the removal of many of these factors from the chromatin [165–169].
Whether or not phosphorylation of mSWI/SNF ATPases is causal or is a consequence of mitotic
chromosome condensation remains to be determined. It also remains to be seen whether evidence
supporting or refuting the idea that CK2 and ERK1, the two kinases implicated in modifying the
phosphorylation state of the mSWI/SNF complex during cell cycle progression, function independently
or in a dependent manner. In either case, it appears that dynamic regulation of BRG1 and mSWI/SNF
enzyme phosphorylation and function occurs during mitosis.
2.4. The PKCβ1 Kinase and the Calcineurin (Cn) Phosphatase Act in Opposition to Regulate BRG1
Phosphorylation and Myogenic Differentiation
In the context of skeletal muscle differentiation, a fine-tuned balance of phosphorylation and
dephosphorylation of BRG1 driven by PKCβ1 and calcineurin controls myoblast fate [49]. It is well
known that the calcium-sensitive serine/threonine phosphatase calcineurin [170] contributes to the
differentiation of immortalized and primary myoblasts, and for muscle regeneration upon damage
in vivo [171,172]. Calcineurin is a heterodimer formed by a catalytic and a regulatory subunit [173,174].
The mechanism of action of calcineurin was characterized in lymphocytes. Active calcineurin
dephosphorylates the TF nuclear factor of activated T-cell (NFAT), leading to its nuclear translocation,
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where it regulates gene expression by binding to promoter regions of target genes [175–178]. During
myogenesis, NFAT binds to target promoters in a calcineurin-dependent manner and contributes
to differentiation, the determination of fiber type, the number of primary fibers, and the growth
of multinucleated muscle cells (Figure 3) [162,179–184]. Calcineurin also triggers skeletal muscle
differentiation by mechanisms that are independent of NFAT [185,186]. Other work showed that
calmodulin, a calcium-binding second messenger protein, also interacts with the mSWI/SNF complex in
other cell types and promotes its chromatin remodeling activities in a calcium-dependent manner [187].
Together, the data supported the hypothesis that the mSWI/SNF complex might be a target of calcineurin.
Biology 2020, 9, x FOR PEER REVIEW 8 of 18 
 
an  the growth of multinucleated muscle cells (Figure 3) [162,179–184]. Calcineuri  also triggers 
skeletal muscle differentiation by mechanisms that are independent of NFAT [185,186]. Other work 
showed that calmodulin, a calcium-binding second messenger protein, also interacts ith the 
mSWI/SNF complex in other cell types and promotes its chromatin remodeling activities in a 
calcium-de endent manner [187]. Together, the data supported the hypothesis that the mSWI/SNF 
complex might be a target of calcineurin. 
 
Figure 3. Antagonistic roles of PKCβ1 and calcineurin in myogenesis. PKCβ1 interacts with and 
phosphorylates BRG1 to block differentiation. Upon myogenic stimulus, calcineurin 
dephosphorylates BRG1 and the TF nuclear factor of activated T-cell (NFAT), enabling chromatin 
remodeling at myogenic loci, myogenic gene expression, and skeletal muscle differentiation. 
Studies in primary and immortalized myoblasts demonstrated that calcineurin inhibition 
blocked chromatin remodeling and expression of myogenic genes without affecting the expression 
of the lineage determining master regulators for myogenesis, MyoD and Myf5. As a result, 
differentiation was inhibited [49]. Importantly, calcineurin inhibition also led to 
hyperphosphorylation of the BRG1 ATPase of mSWI/SNF enzymes (Figure 3). Efforts to identify the 
kinase that opposes calcineurin function relied on software predictors of kinase activity and 
screening of inhibitors against those kinases. In a key experiment, inhibition of PKCβ kinases 
rescued the effect of calcineurin inhibition on myogenic differentiation. The simplest interpretation 
of such results is that in the absence of PKCβ1 activity, there was no consequence of calcineurin 
inhibition because there were no phosphate groups to remove from the substrate. Knockdown 
studies identified PKCβ1 as the specific isoform responsible. In vitro work identified serine residues 
N- and C-terminal to the bromodomain of BRG1 as targets of PKCβ1 and calcineurin [49]. Site 
directed mutagenesis studies demonstrated that mutation of these sites to phosphomimetic residues 
prevented myogenesis because the phosphomimetic BRG1 mutant was unable to bind to myogenic 
promoters while mutation of PKCβ1 target sites to non-phosphorylatable (alanine) residues had no 
effect on chromatin binding or differentiation [49,188]. Calcineurin inhibition also blocked the 
interaction of other subunits of the mSWI/SNF complex with myogenic promoters [188]. This raises 
the possibility of regulated dephosphorylation of other mSWI/SNF subunits or an indirect effect 
due to the failure to dephosphorylate BRG1. The work identifies a kinase and phosphatase working 
in opposition to each other to dynamically regulate the activity of a chromatin remodeling enzyme 
Figure 3. Antagonistic roles of PKCβ1 and calcineurin in myogenesis. PKCβ1 interacts with and
phosphorylates BRG1 to block differentiation. Upon myogenic stimulus, calcineurin dephosphorylates
BRG1 and the TF nuclear factor of activated T-cell (NFAT), enabling chromatin remodeling at myogenic
loci, myogenic gene expression, and skeletal muscle differentiation.
Studies in primary and immortalized myoblasts demonstrated that calcineurin inhibition blocked
chromatin remodeling and expression of myogenic genes without affecting the expression of the lineage
determining master regulators for myogenesis, MyoD and Myf5. As a result, differentiation was
inhibited [49]. Importantly, calcineurin inhibition also led to hyperphosphorylation of the BRG1 ATPase
of mSWI/SNF enzymes (Figure 3). Efforts to identify the kinase that opposes calcineurin function
relied on software predictors of kinase activity and screening of inhibitors against those kinases. In a
key experiment, inhibition of PKCβ kinases rescued the effect of calcineurin inhibition on myogenic
differentiation. The simplest interpretation of such results is that in the absence of PKCβ1 activity,
there was no consequence of calcineurin inhibition because there were no phosphate groups to remove
from the substrate. Knockdown studies identified PKCβ1 as the specific isoform responsible. In vitro
work identified serine residues N- and C-terminal to the bromodomain of BRG1 as targets of PKCβ1
and calcineurin [49]. Site directed mutagenesis studies demonstrated that mutation of these sites to
phosphomimetic residues prevented myogenesis because the phosphomimetic BRG1 mutant was
unable to bind to myogenic promoters while mutation of PKCβ1 target sites to non-phosphorylatable
(alanine) residues had no effect on chromatin binding or differentiation [49,188]. Calcineurin inhibition
also blocked the interaction of other subunits of the mSWI/SNF complex with myogenic promoters [188].
This raises the possibility of regulated dephosphorylation of other mSWI/SNF subunits or an indirect
Biology 2020, 9, 152 9 of 18
effect due to the failure to dephosphorylate BRG1. The work identifies a kinase and phosphatase
working in opposition to each other to dynamically regulate the activity of a chromatin remodeling
enzyme as part of the overall regulatory mechanism governing the initiation of myogenic differentiation
(Figure 3).
3. Conclusions
The effect of kinases and phosphatases on mSWI/SNF chromatin remodeling enzymes during
myoblast proliferation and differentiation are intriguing and represent another mechanism for cells
to regulate differentiation. To date, each characterized pathway has been studied separately, and the
crosstalk between these different regulatory signaling remains an important aspect to address. Similarly,
evidence for the regulation of mSWI/SNF enzyme function by phosphorylation due to specific kinases
exists in contexts other than myogenesis. For example, BAF60c is phosphorylated by PKCζ/λ in response
to insulin, resulting in lipogenic gene transcription in liver [52]. BRG1 phosphorylation dependent on
the kinase ataxia telangiectasia mutated (ATM) is a mechanism by which the ATPase contributes to
double-strand break repair, as the phosphorylation enhances BRG1 binding to γ-H2AX-containing
nucleosomes [189]. However, there are a limited number of cell types in which multiple signaling
pathways have been implicated in the regulation of mSWI/SNF-dependent processes. Consequently,
myoblast proliferation and differentiation represent an exceptional opportunity to take studies of
regulated phosphorylation to the next level, which would be to understand how different signaling
pathways converge on the same set of target proteins. Whether signaling pathways function
independently, are temporally regulated, are dependent on other pathways, or work in a cooperative
manner is largely unknown. Given that most, if not all, of the mSWI/SNF component proteins are
phosphoproteins, we believe it is highly likely that at least some signaling pathways work in a
concerted manner (Figure 4), and that additional signaling pathways affecting mSWI/SNF proteins
phosphorylation are yet to be discovered.
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complex during myogenesis. Schematic representation of post-natal myogenesis and indications of
when specific kinases and phosphatases that control the activity of the mSWI/SNF complex act.
In summary, mSWI/SNF enzymes are essential chromatin remodelers that modulate the proper
growth and differentiation of mammalian cells. Dysregulation of mSWI/SNF complex activity can
lead to consequences in transcriptional regulation, devel pme t, and metabolic homeostasis that may
pr gress into severe p thologies such s cancer. Therefore, it is necessary to continue to advance our
knowledge of th regulatory events that control the physical and functional states of individual subunit
proteins and the enzyme complex. R versible cell signaling events that cause phosphorylation and
dephosphorylation play major roles in most aspects of cell and developmental biology. The work
summarized in this review demonstrat s that regulation of the mSWI/SNF enzyme assembly, chromatin
binding, and chromatin remodeling activities are also targets for th se kinases and phos hatases
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(Figure 4). Further dissection of these regulatory mechanisms will reveal insights into the functionality
of the mSWI/SNF complex as well as the impact of chromatin remodeling enzyme function on human
development and health.
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